MesenFlow Technologies

02/01/2019

MesenFlow Technologies is proud to be part of a study on circadian rhythms in leukocyte trafficking, published in .
What a fantastic way to end the year.
We wish our friends and colleagues a Happy New Year for 2019!

Leukocytes continuously circulate throughout the body. He et al. demonstrate that trafficking patterns of major leukocyte subsets occur in a rhythmic manner dependent on the time-of-day-dependent expression of lineage- and tissue-specific factors. This influences the inflammatory response and leuke...

13/02/2018

Commentary on the paper in Nature Comms, with the founders of MesenFlow. Applying translational technologies to cancer therapy.

For a tumour to grow, it must develop blood vessels that supply nutrients and oxygen. Preventing tumor vascularization is therefore an interesting anti-tumor therapy that has been explored over the last ten years. But how to be truly effective? By identifying two cytokines, key factors in the recrui...

05/02/2018

Valdiating a translational approach in the treatment of cancer & chronic inflammation. A radio interview with author Adama Sidibe about a recent publication in Nature Comms. Further validation of the MesenFlow strategy (In French).

Comment priver de manière ciblée les cellules cancéreuses de leur nourriture et de leur oxygène? C'est l'objet d'une recherche menée à l'Université de Genève (Unige). Les explications d'Adama Sidibé, chercheur au Département de physiologie et métabolisme cellulaire du Centre médical univ...

01/02/2018

Translational medicine in action, and a validation of the MesenFlow approach.
Mesechymal factors play a key role in regulating human monocyte function, in chronic inflammation and cancer.

Circulating myeloid cells can leave the vasculature to infiltrate tumours and are thought to contribute to tumour angiogenesis. Here the authors live image monocytes that migrate to xenograft tumours and map an extravasation cascade of human proangiogenic monocytes into the tumour.

18/10/2017

I have just registered for this. Are you coming too?

14/05/2017

MesenFlow Technologies will be attending the ESM-EVBO 2017 in Geneva. Be sure to check out our stall. http://esm-evbo2017.org

Most diseases are related to the function of the microvasculature, and ‘vessels’ are involved in more than half of human deaths in western countries. Indeed, vessels are tightly linked to numerous pathologies, including atherosclerosis and related cardiovascular diseases (e.g., myocardial infarct, s...

14/05/2017

Our Services

02/05/2017